Compare Incyte Corporation (INCY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Monster Beverage Corp — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Monster Beverage Corp trades at $95.05 (market cap $93.35B). The key difference: Monster Beverage Corp is far larger — about 4× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| INCY | MNST | |
|---|---|---|
Market Cap | $23.11B | $93.35B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $99.94 |
52-Week Low | $67.38 | $58.75 |
Enterprise Value | $19.13B | $91.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Monster Beverage (MNST) trades at $95.79, down 1.75% over 24 hours but near its 52-week high of $99.53. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $8.29B in 2025, and robust profitability margins. A 2-for-1 stock split announced for August 2026 reflects confidence, while technical indicators signal a bullish trend with support at $94.
Outlook remains positive driven by international expansion and product innovation, with a consensus price target of $97.83 offering modest upside. Risks include high valuation multiples and competitive pressures in the energy drink sector. Analyst sentiment is predominantly bullish, supporting a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
